Best Biotech Stocks To Follow Today – November 3rd

Moderna, Natera, Vertex Pharmaceuticals, Regeneron Pharmaceuticals, and AbbVie are the five Biotech stocks to watch today, according to MarketBeat’s stock screener tool. Biotech stocks are shares of publicly traded companies that develop products and technologies using biological processes, such as pharmaceuticals, vaccines, gene therapies, and diagnostic tools. For investors, these stocks can offer substantial growth potential but often carry significant risks because of clinical-trial results, regulatory decisions, and the uncertainty of commercial success. These companies had the highest dollar trading volume of any Biotech stocks within the last several days.

Moderna (MRNA)

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.

Moderna stock traded up $11.62 during midday trading on Tuesday, reaching $232.45. The stock had a trading volume of 4,574,081 shares, compared to its average volume of 12,601,743. The company has a market capitalization of $92.80 billion, a P/E ratio of -29.12 and a beta of 1.09. The company has a current ratio of 2.29, a quick ratio of 2.18 and a debt-to-equity ratio of 0.09. Moderna has a 12 month low of $22.28 and a 12 month high of $254.48. The company has a fifty day moving average price of $184.00 and a two-hundred day moving average price of $87.42.

Natera (NTRA)

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

Natera stock traded up $11.15 during mid-day trading on Tuesday, hitting $390.07. 1,908,172 shares of the company traded hands, compared to its average volume of 1,411,940. Natera has a one year low of $181.00 and a one year high of $437.41. The stock has a fifty day moving average price of $378.00 and a 200-day moving average price of $267.14. The stock has a market cap of $56.23 billion, a price-to-earnings ratio of -287.25 and a beta of 1.55.

Vertex Pharmaceuticals (VRTX)

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.

Shares of VRTX stock traded down $18.24 during trading hours on Tuesday, reaching $534.91. 988,401 shares of the company traded hands, compared to its average volume of 1,387,258. The firm has a 50-day moving average price of $523.32 and a 200 day moving average price of $479.96. Vertex Pharmaceuticals has a 12-month low of $403.16 and a 12-month high of $568.67. The company has a market cap of $135.76 billion, a P/E ratio of 31.12, a P/E/G ratio of 2.54 and a beta of 0.28.

Regeneron Pharmaceuticals (REGN)

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Shares of REGN traded up $6.34 during midday trading on Tuesday, hitting $967.60. The stock had a trading volume of 369,439 shares, compared to its average volume of 824,105. Regeneron Pharmaceuticals has a 1 year low of $591.52 and a 1 year high of $974.36. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.34 and a quick ratio of 2.78. The stock’s 50 day moving average is $795.85 and its 200 day moving average is $739.07. The firm has a market cap of $99.62 billion, a PE ratio of 21.37, a price-to-earnings-growth ratio of 1.37 and a beta of 0.16.

AbbVie (ABBV)

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.

ABBV stock traded down $0.37 during trading on Tuesday, hitting $288.47. 1,204,931 shares of the company’s stock traded hands, compared to its average volume of 6,317,111. The firm has a market capitalization of $509.66 billion, a P/E ratio of 49.69, a PEG ratio of 1.31 and a beta of 0.24. AbbVie has a 1 year low of $190.75 and a 1 year high of $298.74. The business has a fifty day simple moving average of $269.81 and a two-hundred day simple moving average of $237.57.